- Obesity Genes Mean Some Folks Must Exercise More for Same Results
- SCOTUS Appears Skeptical of Arguments to Curb Abortion Pill Access
- Sleep Troubles Can Raise Your Blood Pressure: Study
- ADHD Meds Tied to Heart Damage in Young Adult Users
- Could Regular Exercise Cure Your Insomnia? New Research Says Yes
- Black Men Less Likely to Receive Heart Transplants Than White Men or Women
- Could Deep Frying Foods Harm the Brain? Rat Study Suggests It Might
- Human Brains Are Getting Larger With Each Generation
- Animals Catch More Viruses From Us Than We Do From Them
- Young Adults With Migraine May Face Higher Stroke Risk
Statins Don’t Prevent Kidney Disease Progression, Study Finds
The cholesterol-lowering medications known as statins won’t help people with kidney disease avoid dialysis, but the drugs do lower cholesterol in this group, researchers have found.
“Statins had no effect — neither good nor bad — on kidney function,” study author Dr. Richard Haynes, of the University of Oxford in England, said in an American Society of Nephrology news release.
The study included over 6,000 patients with chronic kidney disease who didn’t yet need dialysis, a process in which a machine does some of the kidney’s blood-filtering tasks. About 60 million people worldwide have chronic kidney disease, according to background information in the news release.
People in the study randomly received either the cholesterol-lowering medication Vytorin, which is a combination of simvastatin plus the drug ezetimibe, or an inactive placebo.
The researchers followed the patients for five years. The drug combination lowered LDL cholesterol — the bad type — by an average of approximately 39 milligrams per deciliter compared to the placebo. But, it didn’t affect the need for dialysis or kidney transplants in the study volunteers: about 34 percent in each group needed those treatments.
The study also confirmed that the drugs are safe for people with kidney disease to take. And, the authors noted, the drug’s cholesterol-lowering properties help reduce the risk of heart disease and stroke.
Results of the study were published online May 1 in the Journal of the American Society of Nephrology. The study’s main funder was Merck/Schering-Plough Pharmaceuticals, which makes Vytorin.
More information
For more about kidney disease, go to the National Kidney Foundation.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.